Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay No Longer Expects Advisory Cmte. For Irritable Bowel Drug Calmactin

This article was originally published in The Pink Sheet Daily

Executive Summary

Additional information submitted by company for the IBS agent was too voluminous to be completely reviewed prior to joint committee meeting tentatively set for March, Solvay suggests. FDA action on cilansetron NDA is still expected by April 1.
Advertisement

Related Content

Solvay Preparing Announcement On Cilansetron NDA
Solvay Preparing Announcement On Cilansetron NDA
Solvay Expects Advisory Cmte. Review For Irritable Bowel Agent Cilansetron
Solvay Expects Advisory Cmte. Review For Irritable Bowel Agent Cilansetron
Lotronex Risk Management Plan Should Not Be Changed Until More Safety Data Is Collected, Cmte. Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS061604

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel